CN113144195A - 伴pcsk9功能获得性突变的常染色体显性高胆固醇血症的治疗方法 - Google Patents

伴pcsk9功能获得性突变的常染色体显性高胆固醇血症的治疗方法 Download PDF

Info

Publication number
CN113144195A
CN113144195A CN202110182897.4A CN202110182897A CN113144195A CN 113144195 A CN113144195 A CN 113144195A CN 202110182897 A CN202110182897 A CN 202110182897A CN 113144195 A CN113144195 A CN 113144195A
Authority
CN
China
Prior art keywords
ser
gly
thr
leu
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202110182897.4A
Other languages
English (en)
Chinese (zh)
Inventor
G·斯维尔戈尔德
S·梅利斯
W·J·萨赛拉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of CN113144195A publication Critical patent/CN113144195A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Mycology (AREA)
CN202110182897.4A 2013-05-30 2014-05-29 伴pcsk9功能获得性突变的常染色体显性高胆固醇血症的治疗方法 Pending CN113144195A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201361828730P 2013-05-30 2013-05-30
US61/828,730 2013-05-30
US201361889553P 2013-10-11 2013-10-11
US61/889,553 2013-10-11
US201361901212P 2013-11-07 2013-11-07
US61/901,212 2013-11-07
CN201480031344.7A CN105263963B (zh) 2013-05-30 2014-05-29 伴pcsk9功能获得性突变的常染色体显性高胆固醇血症的治疗方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201480031344.7A Division CN105263963B (zh) 2013-05-30 2014-05-29 伴pcsk9功能获得性突变的常染色体显性高胆固醇血症的治疗方法

Publications (1)

Publication Number Publication Date
CN113144195A true CN113144195A (zh) 2021-07-23

Family

ID=51205567

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202110182897.4A Pending CN113144195A (zh) 2013-05-30 2014-05-29 伴pcsk9功能获得性突变的常染色体显性高胆固醇血症的治疗方法
CN201480031344.7A Active CN105263963B (zh) 2013-05-30 2014-05-29 伴pcsk9功能获得性突变的常染色体显性高胆固醇血症的治疗方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201480031344.7A Active CN105263963B (zh) 2013-05-30 2014-05-29 伴pcsk9功能获得性突变的常染色体显性高胆固醇血症的治疗方法

Country Status (12)

Country Link
US (2) US20140356370A1 (https=)
EP (1) EP3004172B1 (https=)
JP (1) JP6423868B2 (https=)
KR (1) KR20160013046A (https=)
CN (2) CN113144195A (https=)
AU (1) AU2014274077B2 (https=)
CA (1) CA2912101A1 (https=)
EA (1) EA201592304A1 (https=)
IL (1) IL242251B (https=)
TW (1) TWI682780B (https=)
WO (1) WO2014194111A1 (https=)
ZA (1) ZA201507798B (https=)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
US20130064834A1 (en) 2008-12-15 2013-03-14 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to pcsk9
SG192117A1 (en) 2011-01-28 2013-08-30 Sanofi Sa Human antibodies to pcsk9 for use in methods of treating particular groups of subjects
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
HUE069234T2 (hu) 2011-09-16 2025-02-28 Regeneron Pharma Eljárások lipoprotein(a)-szint csökkentésére proprotein-konvertáz szubtilizin/kexin 9 (PCSK9) inhibitorának beadásával
US9255154B2 (en) 2012-05-08 2016-02-09 Alderbio Holdings, Llc Anti-PCSK9 antibodies and use thereof
US10111953B2 (en) 2013-05-30 2018-10-30 Regeneron Pharmaceuticals, Inc. Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
US10494442B2 (en) 2013-06-07 2019-12-03 Sanofi Biotechnology Methods for inhibiting atherosclerosis by administering an inhibitor of PCSK9
ES2914978T3 (es) * 2013-10-11 2022-06-20 Sanofi Biotechnology Uso de un inhibidor de PCSK9 para tratar hiperlipidemia
CN118105480A (zh) 2013-11-12 2024-05-31 赛诺菲生物技术公司 用于与pcsk9抑制剂一起使用的给药方案
US9034332B1 (en) 2014-07-15 2015-05-19 Kymab Limited Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment
US9051378B1 (en) 2014-07-15 2015-06-09 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US9045548B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision Medicine by targeting rare human PCSK9 variants for cholesterol treatment
US9023359B1 (en) 2014-07-15 2015-05-05 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US8883157B1 (en) 2013-12-17 2014-11-11 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US9914769B2 (en) 2014-07-15 2018-03-13 Kymab Limited Precision medicine for cholesterol treatment
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US9150660B1 (en) 2014-07-15 2015-10-06 Kymab Limited Precision Medicine by targeting human NAV1.8 variants for treatment of pain
US9139648B1 (en) 2014-07-15 2015-09-22 Kymab Limited Precision medicine by targeting human NAV1.9 variants for treatment of pain
KR20230074283A (ko) 2014-07-16 2023-05-26 사노피 바이오테크놀로지 이형접합성 가족성 고콜레스테롤혈증(heFH) 환자의 치료방법
AR102198A1 (es) 2014-10-09 2017-02-08 Regeneron Pharma Proceso para reducir partículas subvisibles en una formulación farmacéutica
WO2016100615A2 (en) * 2014-12-18 2016-06-23 The University Of Chicago Methods and composition for neutralization of influenza
JP2018523684A (ja) 2015-08-18 2018-08-23 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． リポタンパク質アフェレーシスを受けている高脂血症の患者を治療するための抗ｐｃｓｋ９阻害抗体
RU2769282C2 (ru) 2016-06-20 2022-03-30 Кимаб Лимитед Анти-PD-L1 и IL-2 цитокины
US11020686B2 (en) 2016-08-16 2021-06-01 Regeneron Pharmaceuticals, Inc. Methods for quantitating individual antibodies from a mixture
JP7102401B2 (ja) 2016-10-25 2022-07-19 リジェネロン・ファーマシューティカルズ・インコーポレイテッド クロマトグラフィーデータ解析のための方法およびシステム
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
JP7050807B2 (ja) 2017-04-13 2022-04-08 カディラ ヘルスケア リミティド 新規ペプチドベースのｐｃｓｋ９ワクチン
AU2018291702A1 (en) * 2017-06-30 2020-02-06 Jiangsu Hengrui Medicine Co., Ltd. Pharmaceutical composition comprising PCSK-9 antibody and use thereof
CA3073935A1 (en) 2017-09-19 2019-03-28 Regeneron Pharmaceuticals, Inc. Methods of reducing particle formation and compositions formed thereby
IL319165A (en) 2017-12-13 2025-04-01 Regeneron Pharma Apparatus and methods for managing support of a chromatography column substrate and related methods
TWI853823B (zh) 2018-07-02 2024-09-01 美商里珍納龍藥品有限公司 自混合物製備多肽之系統及方法
BR112021013807A2 (pt) 2019-01-18 2021-11-30 Astrazeneca Ab Inibidores de pcsk9 e seus métodos de uso
MX2021008661A (es) 2019-01-18 2021-08-19 Astrazeneca Ab Inhibidores de la pcsk9 y metodos de uso de los mismos.
EA202192422A1 (ru) 2019-03-05 2021-12-09 Ридженерон Фармасьютикалз, Инк. Человеческий сывороточный альбумин в составах
IL292973B2 (en) * 2019-11-18 2026-03-01 Ad Pharmaceuticals Co Ltd Anti-PCSK9 antibody and its use
WO2021119321A1 (en) 2019-12-10 2021-06-17 Regeneron Pharmaceuticals, Inc. Use of a pcsk9 inhibitor to treat homozygous familial hypercholesterolemia
CN116171161A (zh) 2020-08-25 2023-05-26 雷杰纳荣制药公司 用pcsk9和ldlr调节剂治疗败血症
CN116189765B (zh) * 2023-02-23 2023-08-15 上海捷易生物科技有限公司 一种iPS细胞遗传学风险评估系统及应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
EP1471152A1 (en) * 2003-04-25 2004-10-27 Institut National De La Sante Et De La Recherche Medicale (Inserm) Mutations in the human PCSK9 gene associated to hypercholesterolemia
JO3672B1 (ar) * 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
US8357371B2 (en) 2008-12-15 2013-01-22 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to PCSK9
US20130064834A1 (en) 2008-12-15 2013-03-14 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to pcsk9
AR079336A1 (es) * 2009-12-11 2012-01-18 Irm Llc Antagonistas de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9)
AR088782A1 (es) * 2011-04-29 2014-07-10 Sanofi Sa Sistemas de ensayo y metodos para identificar y caracterizar farmacos hipolipemiantes
AR087305A1 (es) * 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
HUE069234T2 (hu) * 2011-09-16 2025-02-28 Regeneron Pharma Eljárások lipoprotein(a)-szint csökkentésére proprotein-konvertáz szubtilizin/kexin 9 (PCSK9) inhibitorának beadásával

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
RHAINDS D等: "PCSK9 inhibition and LDL cholesterol lowering: The biology of an attractive therapeutic target and critical review of the latest clinical trials", 《CLINICAL LIPIDOLOGY》 *

Also Published As

Publication number Publication date
JP6423868B2 (ja) 2018-11-14
EP3004172A1 (en) 2016-04-13
IL242251B (en) 2020-02-27
US20140356370A1 (en) 2014-12-04
AU2014274077A1 (en) 2015-11-19
TWI682780B (zh) 2020-01-21
JP2016522211A (ja) 2016-07-28
AU2014274077B2 (en) 2019-09-26
CN105263963A (zh) 2016-01-20
ZA201507798B (en) 2017-04-26
WO2014194111A1 (en) 2014-12-04
EA201592304A1 (ru) 2016-04-29
HK1216896A1 (en) 2016-12-09
US20190330371A1 (en) 2019-10-31
CA2912101A1 (en) 2014-12-04
EP3004172B1 (en) 2019-11-27
KR20160013046A (ko) 2016-02-03
CN105263963B (zh) 2021-03-05
TW201536315A (zh) 2015-10-01

Similar Documents

Publication Publication Date Title
KR101964031B1 (ko) 전구단백질 전환효소 서브틸리신 켁신-9 (ＰＣＳＫ9)의 억제제를 투여함으로써 지질단백질(ａ)의 농도를 낮추는 방법
CN113144195A (zh) 伴pcsk9功能获得性突变的常染色体显性高胆固醇血症的治疗方法
KR101699707B1 (ko) Ｐｃｓｋ9에 대한 고친화성 사람 항체
AU2013302925B2 (en) Anti-PCSK9 antibodies with pH-dependent binding characteristics
KR101781786B1 (ko) 사람 안지오포이에틴-2에 대한 고 친화성 사람 항체
AU2016302928B2 (en) Anti-PSMA antibodies, bispecific antigen-binding molecules that bind PSMA and CD3, and uses thereof
RU2721279C2 (ru) Антитела человека к pcsk9 для применения в способах лечения конкретных групп индивидуумов
KR20160013047A (ko) 전단백질 전환효소 서브틸리신 켁신-9 (ｐｃｓｋ9)의 억제제를 투여함으로써 잔여 콜레스테롤 및 지단백 분획을 낮추는 방법
KR101896129B1 (ko) 인간 tnf-유사 리간드 1a(tl1a)에 대한 인간 항체
KR102111941B1 (ko) 항-ａｓｉｃ1 항체 및 그 용도
KR20180038020A (ko) 항-angptl８ 항체 및 이의 용도
KR20170102328A (ko) 에볼라 바이러스 당단백질에 대한 인간 항체
KR20240128136A (ko) Gdf8 억제제를 사용하여 강도 및 기능을 증가시키는 방법
KR20150005666A (ko) Fel d1에 대한 사람 항체 및 그것의 사용방법
KR20150003256A (ko) 항-ｈｌａ-ｂ＊27 항체 및 이의 용도
KR20140014067A (ko) 항-cd48 항체 및 그의 용도
KR20150023387A (ko) 항-ｅｇｆｒ 항체 및 이의 용도
KR20140069331A (ko) 항-ＥｒｂＢ3 항체 및 이의 용도
KR20090088936A (ko) 사람 델타 유사 리간드 4에 대한 사람 항체
TW201201838A (en) Antibodies to human GDF8
AU2019226551B2 (en) Methods for altering body composition
AU2019329958B2 (en) Methods and compositions for treating subjects having rheumatoid arthritis
KR20190078650A (ko) 항-angptl8 항체를 사용하는 비만의 치료 방법
KR20190075133A (ko) 렙틴 수용체에 길항하는 항원-결합 단백질
KR20190040320A (ko) 항-그렘린-1 (grem1) 항체 및 폐동맥 고혈압을 치료하기 위한 그의 사용 방법

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20210723